An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer
Elsevier ·
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer. // European Urology Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2588931126000519?dgcid=rss_sd_all
An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer. European Urology Oncology. https://www.sciencedirect.com/science/article/pii/S2588931126000519?dgcid=rss_sd_all
“An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer.” European Urology Oncology.
@article{article154149,
title = {An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer},
journal = {European Urology Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2588931126000519?dgcid=rss_sd_all}
}